DRREDDY get generic Semaglutide injection approval in Brazil

Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) DRREDDY has received regulatory approval in Brazil for its generic Semaglutide injection, for adults with uncontrolled type 2 diabetes. The estimated addressable market for generic semaglutide in Brazil is $800 million. What happened: Dr. Reddy’s will launch with Aché, a Brazilian pharmaceutical manufacturer, under a co-commercialization partnership. Brazil follows earlier product filings in Canada and India. The company targets a combined supply of 6 million to 7 million semaglutide injector pens across key markets in H2 FY27. Why it matters: Brazil gives Dr. Reddy’s a large GLP-1 market where the company can sell. It also adds a growth line as older generics lose revenue after the loss of exclusivity on legacy oncology brands. My view: Treat $800 million as the size of the pool, not Dr. Reddy’s revenue. Approval is a permit. Sales depend on supply, and supply depends on the pen scale-up. The Q1 FY27 batch provision of ₹239.7 crore on semaglutide API shows what the ramp-up has cost so far. Aché brings local distribution and retail access, which cuts entry risk. Profit sharing terms are not disclosed, so margin impact is uncertain. Pricing will also come under pressure as more generic filers enter. What I am watching: the Brazil launch date with Aché, the Q3 relaunch of the Obeda brand, and whether pen supply tracks the H2 FY27 target. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.